Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-12-12
2006-12-12
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
07148257
ABSTRACT:
Methods for treating mesothelioma comprising administering the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) are disclosed.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5055608 (1991-10-01), Marks et al.
patent: 5175191 (1992-12-01), Marks et al.
patent: 5369108 (1994-11-01), Breslow et al.
patent: 5608108 (1997-03-01), Marks et al.
patent: 5654333 (1997-08-01), Samid
patent: 5700811 (1997-12-01), Breslow et al.
patent: 5773474 (1998-06-01), Breslow et al.
patent: 5932616 (1999-08-01), Breslow et al.
patent: 6087367 (2000-07-01), Breslow et al.
patent: 6231880 (2001-05-01), Perrine
patent: 6239176 (2001-05-01), Nudelman et al.
patent: 6262116 (2001-07-01), Pandolfi et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6495719 (2002-12-01), Lan-Hargest et al.
patent: 6511990 (2003-01-01), Breslow et al.
patent: RE38506 (2004-04-01), Breslow et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 2003/0082666 (2003-05-01), Kammer et al.
patent: 2003/0114525 (2003-06-01), Kammer et al.
patent: 2003/0161830 (2003-08-01), Jackson et al.
patent: 2003/0235588 (2003-12-01), Richon et al.
patent: 2004/0266818 (2004-01-01), Breslow et al.
patent: 2004/0072735 (2004-04-01), Richon et al.
patent: 2004/0087631 (2004-05-01), Bacopoulos et al.
patent: 2004/0122101 (2004-06-01), Miller et al.
patent: 2004/0127522 (2004-07-01), Chiao et al.
patent: 2004/0127523 (2004-07-01), Bacopoulos et al.
patent: 2004/0132643 (2004-07-01), Fojo et al.
patent: 2004/0132825 (2004-07-01), Bacopoulos et al.
patent: 2004/0167184 (2004-08-01), Wiech et al.
patent: 2004/0002506 (2004-12-01), Breslow et al.
patent: WO 95/31977 (1995-11-01), None
patent: WO 98/9965 (1998-09-01), None
patent: WO 98/40080 (1998-09-01), None
patent: WO 98/55449 (1998-12-01), None
patent: WO 0021979 (2000-04-01), None
patent: WO 00/71703 (2000-11-01), None
patent: WO 01/16106 (2001-03-01), None
patent: WO 01/18171 (2001-03-01), None
patent: WO 01/38322 (2001-05-01), None
patent: WO 01/70675 (2001-09-01), None
patent: WO 02/15921 (2002-02-01), None
patent: WO 02/22577 (2002-03-01), None
patent: WO 02/30879 (2002-04-01), None
patent: WO 02/46144 (2002-06-01), None
patent: WO 02/55017 (2002-07-01), None
patent: WO 02/085400 (2002-10-01), None
Andrews et al. (2000).Intl. J. Parasitol. 30: 761-768.
Archer et al. (1998).Proc. Natl. Acad. Sci. USA95: 6791-6796.
Bhalla et al. (2002). “Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells.”American Society of Hematology, 44thMeeting of the American Society of Hematology, Abstract 4611.
Butler et al. (2000).Cancer Res. 60: 5165-5170.
Butler et al. (2001).Clincal Cancer Res. 7: 962-970.
Butler et al. (2002).Proc. Natl. Acad. Sci. USA99: 11700-11705.
Coffey et al. (2000).Medical and Pediatric Oncology35: 577-581.
Coffey et al. (2001).Cancer Res. 61: 3591-3594.
Cohen et al. (1999).Anticancer Res. 19: 4999-5006.
Cohen et al. (2002).Anticancer Res. 22: 1497-1504.
Curtin (2002).Exp. Opin. Ther. Patents12: 1375-1384.
Dressel (2000).Anticancer Res. 20: 1017-1022.
Fei et al. (2002). “Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells.”American Society of Hematology, 44thMeeting of the American Society of Hematology Abstract No. 4602.
Feinman et al. (2002). “The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells.”American Society of Hematology, 44thMeeting of the American Society of Hematology, Abstract No. 3195.
Finnin et al. (1999).Nature401: 188-193.
Furamai et al. (2001).Proc. Natl. Sci. USA98: 87-92.
Grunstein (1997).Nature389: 349-352.
He et al. (2001).J. Clin. Investigation108: 1321-1330.
Hockly et al. (2003).Proc. Natl. Acad. Sci. USA100: 2041-2046.
Kelly et al. (2001). “Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity.”American Society of Clinical Oncology, Abstract No. 344.
Kelly et al. (2002). “Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity.”American Society of Clinical Oncology, 38thAnnual Meeting of the American Society of Clinical Oncology, Nov. 7-10, 2002, Abstract No. 1831.
Kelly et al. (2002). “A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).”European J. Cancer38(Suppl. 7): 88, Abstract No. 286.
Kim et al. (1999).Oncogene18: 2461-2470.
Kohge et al. (1998).Biochem. Pharmacol. 56: 1359-1364.
Komatsu et al. (2001).Cancer Res. 61: 4459-4466.
Kouraklis and Theocharis (2002).Curr. Med. Chem.Anti-Cancer Agents2: 477-484.
Lee et al . (2001).Cancer Res. 61: 931-934.
Lin et al. (1998).Nature391: 811-814.
Mai et al. (2001).OPPI Briefs33: 391-394.
Marks et al. (2000).J. of the Natl. Cancer Institute92: 1210-1215.
Marks et al. (2001).Clinical Cancer Res. 7: 759-760.
Marks et al. (2001).Curr. Opin. In Oncology13: 477-483.
Marks et al. (2001).Nature Reviews1: 194-202.
Miller et al. (2003).J Med Chem. 46: 5097-5116.
Munster et al. (2001).Cancer Res. 61: 8492-8497.
O'Connor et al. (2002). “Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHLO and hodgkin's disease (HD)).”American Society of Clinical Oncology, Dec. 6-10, 2002, Abstract No. 4742.
Qui et al. (2000).Mol. Biol. Cell11: 2069-2083.
Richon et al. (1996).Proc. Natl. Acad. Sci. USA93: 5705-5708.
Richon et al. (1998).Proc. Natl. Acad. Sci. USA95: 3003-3007.
Richon et al. (2000).Proc. Natl. Acad. Sci. USA97:10014-10019.
Richon and O'Brien (2002).Clinical Cancer Res. 8: 662-664.
Saito et al. (1999).Proc. Natl. Acad. Sci. USA96: 4592-4597.
Sgouros et al. (2002). “Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and Radiation in Human Prostate Tumor Spheroids.”American Society of Clinical Oncology, Abstract No. 105.
Stowell et al. (1995).J. Med. Chem. 38: 1411-1413.
Su et al. (2000).Cancer Res. 60: 3137-3142.
Suzuki et al. (1999).J. Med. Chem. 42: 3001-3003.
Van Lint et al. (1996).Gene Expression5: 245-253.
Vrana et al. (1999).Oncogene18: 7016-7025.
Webb et al. (1999).J. Biol. Chem. 274: 14280-14287.
Yoshida et al. (1990).J. Biol. Chem. 265: 17174-17179.
Yoshida et al. (1995).BioEssays17: 423-430.
Zhou et al. (1999).Gene233: 13-19.
Zhou et al. (2000).Proc. Natl. Acad. Sci. USA97: 1056-1061.
Zhou et al. (2000).Proc. Natl. Acad. Sci. USA97: 14329-14333.
Zhou et al. (2001).Proc. Natl. Acad. Sci. USA98: 10572-10577.
Adams and Elliott (2000).Oncogene19: 6687-6692.
Bates et al. (1999).Proc. American Society of Clinical Oncology18: 180a, Abstract No. 693.
Foster et al. (1997).Invest. New Drugs15: 187-194.
Gojo et al. (2002).Blood100: Abstract No. 2198.
Gore and Carducci (2000).Exp. Opin. Invest. Drugs9: 2923-2934.
Huang and Pardee (2000).Molecular Medicine6: 849-866.
Johnstone, R. (2002).Nature Reviews Drug Discovery1: 287-299.
Kelly et al. (2002).Exp. Opin. Invest. Drugs11:1695-1713.
Kelly et al. (2002).Proc. American Society of Clinical Oncology21: 6b, Abstract No. 1831.
Kelly et al. (2001).Proc. American Society of Clinical Oncology20: 87a, Abstract No. 344.
Kosugi et al. (2001).Jpn. J. Cancer Res. 92: 529-536.
Marshall et al. (2002).J. Exp. Therapeutics and Oncology2: 325-332.
Piekarz et al. (2001).Blood98: 2865-2868.
Prakash et al. (2001).Invest. New Drugs19: 1-11.
Rha et al. (1993).J. Korean Med. Sci. 8:251-256.
Rifkind et al. (2002).224thACS National Meeting, Boston, MA, Abstract No. 226.
Sandor et al. (2002).Clinical Cancer Research8: 718-728.
Secrist et al. (2003).Curr. Opin. Invest. Drugs4:1422-1427.
Summerhayes, M. (2001).J. Oncol. Pharm. Prac. 7: 107-125.
Vigushin, D. (2002).Current Opin
Bacopoulos Nicholas G.
Chiao Judy H.
Miller Thomas A.
Paradise Carolyn M.
Richon Victoria M.
Elrifi, Esq. Ivor R.
Merck HDAC Research, LLC
Mintz Levin Cohn Ferris Glovsky and Popeo PC
Sloan-Kettering Institute for Cancer Research
Spivack Phyllis G.
LandOfFree
Methods of treating mesothelioma with suberoylanilide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating mesothelioma with suberoylanilide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating mesothelioma with suberoylanilide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3696699